Together our data suggest that the administration of tamoxifen or fulvestrant or depletion of estrogens concurrently with RT may increase the effectiveness of radiotherapy, demonstrating that this could be an effective treatment intensification strategy for patients with locally advanced ER+ breast cancer at high risk for locoregional recurrence. The gene discussed is ESR1; the disease is breast cancer.